evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,550 questions · 1,617 findings · 161 reviews · Neonatal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 238 · 14.7%GRADE not reported 76 · 4.7%Very low 377 · 23.3%Low 567 · 35.1%Moderate 285 · 17.6%High 74 · 4.6%

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

BPD or death by it prior to 37 weeks' PMA (outcomes collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in BPD or death by it prior to 37 weeks' PMA (outcomes collected… compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Severe (grade 3 or greater) intraventricular hemorrhage (IVH) on cranial ultrasound ‐ not reported · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in severe IVH (grade 3 or 4) compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Any late‐onset sepsis ‐ all infants · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in late‐onset sepsis (> 72 hours of age) compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Necrotizing enterocolitis (suspected or proven) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in suspected or proven NEC compared with placebo (high certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Type 1 ROP or death before determination of ROP outcome using the adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP or death before determination of ROP outcome using the… compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

Type 1 ROP including adjudicated ROP outcome · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in type 1 ROP including adjudicated ROP outcome compared with placebo (moderate certainty).

1 finding from 1 review

Inositol supplementation IV initially followed by enteral administration (repeat doses of 80 mg/kg/day) in preterm infants born at less than 30 weeks' PMA vs placebo

All‐cause mortality (outcome collected through first event: death, hospital discharge, hospital transfer, or 120 days after birth) · preterm infants with or at risk of respiratory distress syndrome

Inositol supplementation IV initially followed by enteral… showed no clear difference in all‐cause mortality (outcome collected through first event: death,… compared with placebo (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Early developmental intervention programmes vs standard follow‐up

Cognitive outcome · preterm infants
3 findings from 1 review

Exposure vs no exposure to the smell and taste of milk with tube feeds

Late infection during hospitalisation (bacterial or fungal infection confirmed by presence of blood or CSF infection, with initiation of symptoms > 48 hours after birth) · preterm infants

Exposure showed no clear difference in late infection during hospitalisation (bacterial or fungal infection… compared with no exposure to the smell and taste of milk with tube feeds (moderate certainty).

1 finding from 1 review

Superoxide dismutase (SOD) vs placebo

Severe retinopathy of prematurity (stage II or greater)№ of participants: 244(1 RCT) · preterm infants at risk for bronchopulmonary dysplasia

It is very uncertain whether superoxide dismutase (SOD) changes severe retinopathy of prematurity (stage II or greater)№ of… compared with placebo (very low certainty).

1 finding from 1 review

Methylxanthine vs placebo or control

Positive‐pressure ventilation after institution of treatment · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine may leads to lower positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

1a.'Clinical apnea' after initiation of treatment – doxapram compared to no treatment for the prevention of reintubation · prevention of reintubation

The review found no eligible studies for this question.

2 findings from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

1c.'Clinical apnea' after initiation of treatment – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

Doxapram may leads to lower 1c.'Clinical apnea' after initiation of treatment – doxapram as an… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

2b. Failed apnea reduction after 2–7 days – doxapram compared to alternative treatment for the prevention of reintubation · prevention of reintubation

It is very uncertain whether doxapram changes 2b. Failed apnea reduction after 2–7 days – doxapram compared to… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).

1 finding from 1 review

Doxapram vs no treatment, placebo, methylxanthine (including theophylline, aminophylline, or caffeine), or

2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct to methylxanthine compared to methylxanthine alone for the prevention of reintubation · prevention of reintubation

Doxapram showed no clear difference in 2c. Failed apnea reduction after 2–7 days – doxapram as an adjunct… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).

1 finding from 1 review